Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Our study (NCT04800133) aimed to determine the safety and immunogenicity in patients with IEIs receiving a 3-dose primary series of mRNA vaccine BNT162b2 (age 12+) or inactivated whole-virion vaccine CoronaVac (age 3+) in Hong Kong, including Omicron BA.1 neutralization, in a nonrandomized manner. I...

Descripción completa

Detalles Bibliográficos
Autores principales: Leung, Daniel, Mu, Xiaofeng, Duque, Jaime S. Rosa, Cheng, Samuel M. S., Wang, Manni, Zhang, Wenyue, Zhang, Yanmei, Tam, Issan Y. S., Lee, Toby S. S., Lam, Jennifer H. Y., Chan, Sau Man, Cheang, Cheuk Hei, Chung, Yuet, Wong, Howard H. W., Lee, Amos M. T., Li, Wing Yan, Chaothai, Sara, Tsang, Leo C. H., Chua, Gilbert T., Cheong, Kai-Ning, Au, Elaine Y. L., Kwok, Janette S. Y., Chan, Koon Wing, Chong, Patrick C. Y., Lee, Pamela P. W., Ho, Marco H. K., Lee, Tsz Leung, Tu, Wenwei, Peiris, Malik, Lau, Yu Lung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530261/
https://www.ncbi.nlm.nih.gov/pubmed/36203563
http://dx.doi.org/10.3389/fimmu.2022.982155

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530261/
https://www.ncbi.nlm.nih.gov/pubmed/36203563
http://dx.doi.org/10.3389/fimmu.2022.982155

Ejemplares similares